Sumitomo Dainippon Pharma Annual Report 2017
6/102 2016We participate in “Access Accelerated”, the first global partnership activity among global pharmaceutical companies to improve access to healthcare in developing countries. The partnership is focused on improving access to prevention, treatment, and care of non-communicable diseases (NCDs), such as cancers and cardiovascular diseases, in low- and middle-income countries where nearly 80% of NCD-related deaths occur.Contributingto global health”, ong oping on ment, ses y 05Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#6